Long-term follow-up of topiramate and lamotrigine: a perspective on quality of life  by Kaiser, Stefan et al.
doi:10.1053/seiz.2002.0681, available online at http://www.idealibrary.com on
Seizure 2002; 11: 356–360
Long-term follow-up of topiramate and lamotrigine:
a perspective on quality of life
STEFAN KAISER† ‡ , CAROLINE E. SELAI§ & MICHAEL R. TRIMBLE†
†Raymond Way Neuropsychiatry Research Unit, Institute of Neurology, London; ‡Department of
Psychiatry, University of Heidelberg, Germany; §Institute of Neurology, London
Correspondence to: Dr Caroline E. Selai, Institute of Neurology, Queen Square, London WC1N 3BG, UK.
E-mail: c.selai@ion.ucl.ac.uk
We conducted a prospective, long-term audit of lamotrigine and topiramate as add-on treatment for refractory epilepsy. A total
of 55 patients participated in the study. Five years after starting the drug 7/20 patients remained on lamotrigine and 13/35
on topiramate. The patients still on the study drugs showed an improvement in seizure frequency, with 5/7 patients being
seizure free on lamotrigine and 4/13 on topiramate. Furthermore, we assessed quality of life using the quality of life assessment
schedule and found a significant improvement for the patients still on the study drugs. These data suggest that about one third
of the patients on lamotrigine or topiramate as add-on therapy stay on the drug in the long term. These patients are likely to
benefit with respect to objective and subjective outcome measures.
c© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Most patients with epilepsy are well controlled on
monotherapy with one of the standard anti-epileptic
drugs (AEDs). However, for about one third of patients
with refractory epilepsy polytherapy is considered.
This usually involves add-on therapy with one of the
more recently introduced AEDs, such as lamotrigine,
topiramate, gabapentin and vigabatrin. The efficacy
and tolerability of these drugs have been demonstrated
in controlled trials1. However, audits assessing the
longevity of treatment with these agents have reported
a high rate of patients stopping the new drug after
the initial trial period2. There is preliminary evidence
that lamotrigine and topiramate might have the lowest
drop-out rates of the new AEDs3, 4.
In recent years, much attention has been given
to the assessment of health-related quality of life
(HRQL), often abbreviated to quality of life (QOL),
and this is now acknowledged to be an important
outcome measure in the evaluation of health care
interventions. The history, development, and current
status of measures to assess QOL(HRQL) in epilepsy
have been comprehensively reviewed5–7. It is well
documented that the occurrence of seizures and stigma
of epilepsy lead to a variety of physical, psychological
and social problems which have an impact on many
areas such as self-esteem, work, career prospects,
family, leisure, (in)ability to drive and relationships7.
Although QOL has been assessed in clinical trials
of antiepileptic drug therapy8, to our knowledge
this issue has not been addressed by prospective
audits beyond the initial trial period. The impact of
medication on physical, psychological and social well-
being is known, however, to play a role in patients’
satisfaction and compliance with drug treatment7.
Our group has previously investigated patients on
either lamotrigine or topiramate as add-on therapy
over a 6 month period9. The investigators found that
over half of patients were still on the drug (61–65%),
but found a low level of patient satisfaction, when
subjective criteria were included. In the present audit
these patients were followed up 5 years after starting
lamotrigine or topiramate as add-on therapy. In this
study, in addition to measures relating to efficacy and
tolerability of treatment, we assessed QOL at 5 year
follow up.
Taking into account the low level of patient
satisfaction after 6 months, we were expecting only
a minority of the patients to be still on the study
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drugs. Regarding QOL we hypothesized a sustained
improvement in the patients still on the study drug,
while the patients not on the drug were likely to
represent a heterogeneous group in terms of treatment
and QOL.
METHODS
Subjects
Patients who had participated in the previous study
were contacted by telephone. Of the patients started
on topiramate 35/47 (74%) participated in the present
study, two were cognitively unable to complete the
interview, one declined to participate and nine were
lost to follow-up. Of the patients started on lamotrigine
20/26 (77%) completed the interview, while six were
lost to follow-up. All subjects were outpatients in a
tertiary referral center.
Outcome measures
Seizure control
The national hospital seizure severity scale (NHS3)
was used to assess seizure frequency and severity
over the preceding three months10. It contains seven
seizure-related factors and generates a score from 1
to 27. Seizure-related factors are presence of general-
ized convulsions, falls and injuries occurring during
the seizure, incontinence, loss of consciousness,
recovery time and disruptive automatisms.
Drug-related data
The patients current drug regimen was noted. Adverse
events (requiring urgent medical treatment) and side
effects (as perceived by the patient) were recorded.
Adverse events were subjectively measured, i.e. data
on adverse events were elicited directly from the
patient and not from hospital or other notes.
Quality of Life (QOL)
QOL was measured by the quality of life assessment
schedule (QOLAS), a generic, patient-driven semi-
structured QOL assessment, based on the personal
construct theory and repertory grid technique11, 12.
The QOLAS was chosen because it was previously
demonstrated to be more sensitive to change in
patients with epilepsy than some other QOL measures
(generic and disease-specific)12. The QOLAS is a
semi-structured interview which assesses ten areas of
HRQL in five domains (physical, psychological, so-
cial, work/economic and cognitive functioning). The
QOLAS has been used to assess the QOL of people
with a number of neurological disorders, including
epilepsy12, dementia13 and Tourette syndrome14.
During the QOLAS interview the patient is invited to
select two ‘constructs,’ i.e. two items of importance to
them, in each of the five domains. The scores can be
presented as a profile and also as a global score, from
0 to 50, with higher scores indicating a worse HRQL.
In this study the constructs elicited from each patient
during the original base-line interview were used, i.e.
at follow-up, the patient was invited to re-score each
item. See Table 1 for a typical scoring example from
the present study.
Table 1: QOLAS scoring—a typical example.
Domain Construct Construct Domain
score score
Physical Seizures 3
Headaches 2 5
Psychological Anxious 4
Angry (‘why me?’) 4 8
Social/family Can’t do some activities 4
Strain on my family 5 9
Work/daily Had a lot off time off work 4
activities I’m not promoted 3 7
Cognitive Memory 5
Concentration 3 8
Total 37
The full QOLAS interview, which was used in the
base-line research is conducted as follows:
(1) Introduction and rapport-building.
(2) The respondent is invited to recount what is
important for his/her QOL and ways in which
their current health condition is affecting their
QOL. Key constructs are extracted from this
narrative. Prompting is sometimes required.
(3) In total, ten ‘constructs’ are elicited, two
for each of the following domains of QOL:
physical, psychological, social, daily activities
and cognitive functioning (or well-being).
(4) The patient is asked to rate how much of a
problem each of these is now on a 0–5 scale,
where 0= no problem; 1= very slight problem;
2 = mild problem; 3 = moderate problem;
4 = big problem and 5 = it could not be worse.
(5) The patient is asked to rate how much of a
problem they would ‘like’ each of these to be
ideally on a 0–5 scale as above.
(6) At follow-up interview, the respondent’s indi-
vidual constructs are read out to them and they
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Table 2: Patient status at interview.
Lamotrigine Topiramate
On LTG Off LTG Surgery On TPM Off TPM Surgery VNS
Number of patients at present 7/20 10/20 3/20 13/35 18/35 2/35 2/35
Seizure free 5/7 0/10 3/3 4/13 0/18 2/2 0/2
50% reduction most 7/7 4/10 3/3 10/13 7/18 2/2 1/2
severe type
The upper part of the table shows the number of patients who are still on the new AED (on LTG/TPM) and those off the new AED but treated
with other medication (off LTG/TPM). Additionally, those who underwent either surgery (surgery) or implantation of a VNS are included. The
lower part shows the number of patients in each subgroup, who are either seizure free or had at least a 50% reduction in seizure frequency of
the most severe seizure type as assessed by the NHS3.
are invited to re-rate each on the 0–5 scale
for how much of a problem there is with each
‘now’.
Statistical analysis
In order to assess changes in QOL we performed
repeated-measures ANOVA with overall QOLAS
score as dependent measure. Between subject factor
was medication (still on medication/off medication),
within subject factor timepoint (time started on
drug/present).
RESULTS
Medication and seizure frequency
Table 2 shows the number of patients still taking the
original drug. Of the patients started on lamotrigine
7/20 (35%) were still taking the drug, compared to
13/35 (37%) in the topiramate group. A minority of
patients underwent surgery or, in the topiramate group,
implantation of a vagal nerve stimulator (VNS). Of
the postsurgical patients one was still on lamotrigine,
all the other patients with nonmedical treatment were
taken off the drug under study. In the lamotrigine
group, patients discontinued the drug because of side-
effects (4/12), lack of effect (3/12), a combination of
both (3/12) or other reasons (2/12). In the topiramate
group, patients discontinued the drug because of side-
effects (6/22), lack of effect (3/22), a combination of
both (8/22) or other reasons.
Table 2 also shows efficacy of treatment as reflected
by two outcome criteria: (i) no seizures for at least
3 months or (ii) 50% reduction in frequency of the
most severe seizure type as assessed by the NHS3.
Of the seven patients still on lamotrigine five were
seizure free for 3 months and all had at least 50%
reduction in seizure frequency. Of the 13 patients still
on topiramate four were seizure free and 10 had at
least a 50% frequency reduction. Side-effects were
noticed by 2/7 patients still on lamotrigine and 5/13
on topiramate. Two patients on lamotrigine reported
blurred vision and mild dizziness. Three patients
on topiramate complained about excessive daytime
sleepiness and two about emotional instability. No
adverse events were reported.
Quality of life—qualitative data
The QOL issues most frequently mentioned by this
group of patients are shown in Table 3.
Table 3: QOLAS qualitative data. The three most frequently
nominated items per QOLAS domain.
Domain Problem Frequency in %
Physical Seizures 43
Seizure-related
problems 41
Tiredness 27
Psychological Depression 24
Anger (‘why me?’) 22
Anxiety 24
Social Restricted social life 47
Problems with family/
relationships 38
Inability to drive 35
Work/daily activities Unable to work 38
Interference with career 31
Discrimination 15
Cognitive Memory 56
Concentration impaired 25
Thinking 25
Quality of life—statistical analysis
Figure 1 shows the overall QOLAS scores for the
patients started on lamotrigine. Repeated measures
ANOVA showed a highly significant group (on
LTG/off LTG) × timepoint (time drug started/present)
interaction (P < 0.01). Patients still on the drug
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showed an improvement in their QOLAS score from
33.1± 7.6 to 12.7± 10.9. Patients off the drug did not
show a significant change in QOLAS score (34.0±7.7
to 32.9± 8.2).
Fig. 1: Mean overall QOLAS scores from 50 (worst) to 0
(best) for the subgroups still on lamotrigine, off lamotrigine
but medically treated and surgery. Original score in light grey,
present score in dark grey. Error bars represent standard
error of mean.
Figure 2 shows overall QOLAS scores for patients
started on topiramate. Repeated measures ANOVA
showed a significant group (on TPM/off TPM)
× timepoint (time drug started/present) interaction
(P < 0.05). Patients still on the drug showed an
improvement in their QOLAS score from 31.1 ± 8.7
to 21.3 ± 10.6. Patients off the drug did not show a
significant change in QOLAS score (31.4 ± 10.9 to
28.3± 10.7).
Fig. 2: Mean overall QOLAS scores from 50 (worst) to 0
(best) for the subgroups still on topiramate, off topiramate but
medically treated and surgery. Original score in light grey,
present score in dark grey. Error bars represent standard
error of mean.
The small number of patients who underwent
surgery did not allow statistical comparison, but their
data suggest an improvement in QOL.
Relationship between QOL and seizure
frequency
In order to examine the relationship between QOL
and seizure frequency, we conducted an exploratory
correlation analysis. We found a significant correlation
between QOLAS score and frequency of the most
severe seizure type for the lamotrigine (r = 0.7,
P < 0.01) as well as for the topiramate group (r =
0.39, P < 0.05).
DISCUSSION
In this study we have carried out a prospective audit
of patients with refractory epilepsy treated with either
lamotrigine or topiramate as add-on therapy. This
study was not controlled and is limited by a relatively
small sample size. However, it presents data on the
actual clinical experience with two new antiepileptic
agents and more importantly, it includes quality of life
as an outcome measure.
In both medication groups about one third of the
patients remained on the newly introduced drug after
5 years, which was a higher proportion than we
expected. Walker et al. have reported that only 14%
of the patients were still on lamotrigine after 6–
8 years2. Similarly, Lhatoo et al. estimated by using
Cox regression analysis that less than one fourth of
patients with partial epilepsy are likely to continue on
one of the new AEDs after 5 years3. However, in the
Collins et al. study after 50 months 60% were still on
lamotrigine and 50% still on TPM4. The differences
between studies can partially be explained by the
different time periods studied, but more important are
probably differences in the patient population.
Treatment success was indicated by 50% reduction
in seizure frequency in all patients still on lamotrigine
and 10 out of 13 patients in the topiramate group. This
suggests a substantial benefit in objective outcome
measures for those patients still on the drug after
5 years. To our knowledge no study has previously
reported seizure frequency data for lamotrigine or
topiramate after this time period. Caution is necessary
when directly comparing the drugs, because the
two groups were not matched for demographic and
epilepsy related variables.
Our hypothesis that the patients remaining on the
studied drugs would experience an improvement in
QOL was supported by the QOL data. Patients still
on lamotrigine or topiramate showed an improvement
in QOL. This was reflected by significantly lower
QOLAS scores at 5-year follow up as compared to
baseline data. Patients who came off their original
drug and were treated with a different drug regimen,
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showed little overall change in QOL. We assessed
QOL using a semi-structured, patient-driven tech-
nique. The QOLAS has been previously shown to be
sensitive to change in QOL and in one study was
shown to be more sensitive to change than the other
QOL measures used12. When measuring quality of
life a change of greater than 10% is generally thought
to represent clinical as opposed to merely statistical
significance15. Using this criterion, it can be argued
that the substantial decrease of QOLAS scores in our
study shows a clinically significant improvement in
QOL, which reflects the patients’ own views about
what is relevant to their QOL and their perception of
their current status.
The wide variety of factors influencing QOL is
reflected by the diverse issues mentioned by our
patients in the QOLAS interview. Important areas
were seizure-related physical impairment, restricted
social life, inability to work and cognitive prob-
lems, specifically memory. Our correlational analysis
showed that there is a direct relationship between
seizure control and QOL. However, the size of the
correlation and the variety of topics mentioned by the
patients suggests that there are other factors affecting
QOL. It would be interesting to measure these factors
such as reported memory deficits objectively in order
to quantify their impact on QOL.
The relationship between seizure control, side-
effects, adverse events QOL and compliance is com-
plex. Many patients are non- or partially compliant yet
variables such as intelligence, socioeconomic level,
personality, age and education have not correlated well
with electronically monitored compliance (Cramer,
1996)7. The results of the present study suggest that
patients take a number of factors into account when
deciding whether or not to continue their medication.
Of most importance was the balance of side-effects
and seizure frequency. In addition, patients reported
that their decisions were influenced by recent life-
events and a minority of patients stopped the drug
for reasons not related to their epilepsy at all. In this
respect, the interpretation of our data has to be careful
because the reasons for stopping the drug were elicited
retrospectively and we had no data regarding QOL at
the time the decision was actually made. However,
this issue is of major clinical relevance and will be
addressed in further research.
CONCLUSIONS
These long-term follow-up data on the outcome of
treatment with lamotrigine or topiramate suggest that
a substantial minority of about one third of the patients
are likely to stay on these agents in the long-term.
Furthermore, these patients show an improvement in
objective as well as subjective outcome measures
as indexed by seizure frequency and QOLAS score.
However, it remains an open issue how this patient
subgroup can be identified before initiating add-on
therapy with one of the agents under study.
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